Member Info for Davde

Slide 10 clearly says for post pandemic.

The government encouraged the UK diagnostics industry to expand capacity with the lure of large contracts. Remember the RTC, the expensive government loaned equipment and loans the £2m to support resource expansion. As a consequence ODX took the government at face value during a period of national crisis and created manufacturing capacity well beyond what was required for CD4 and any covid sales. That is why the Alva site needed to be disposed of asap. Now you can apportion blame on ODX BoD for being gullible in believing the UK government but imv the UK government have not behaved well in this affair!

Ragnarr the apple pancake recipe sounds good, I would add a bit of cinnamon or ginger powder topped with maple syrup, may have some for my breakfast tomorrow!

"Taxation for the period was £1.7 million (2020: £0.2 million), mainly due to the very low Netherlands cost base and payment timing." The question is how much payment timing v cost base.

A whole day spent discussing a tender award. Yesterday it was where has the £10m gone. Day before was the cost of the funding to support growth being expensive! It's boring and shows agendas. What I want to know is, what does GB have for breakfast each day, via a RNS preferably, so I am kept completely up to date with daily developments, as an addendum any bowel movements appreciated!

Seemo DVRG yahoo historical data gives you the daily/weekly/monthly trade volumes. Does not distinguish between buys/sells. I reckon about a (roughly) quarter to a third of shares have been traded in last year.

Okehurst1 the "news" that ODX may sell CD4 is not new, it was mentioned at the investor meeting and was on the strategy review slide as an option, maybe I am missing something in the chairman's letter.

There are accounts for 20/21. Yes CD4 did incur losses in 19/20 as they were developing the product. CD4 is now approved by WHO, it would be disappointing, after many years of work, if they decided to not produce this test as it is potentially very profitable.

CD4 did not lose £2.5m the bulk of the global health loss related to scaling up for covid tests!

ODX stated that there would £800k sales for CD4 in second half! It is likely to have revenues of circa £10m this year. The health and nutrition business is profitable.

I have never been bothered by a lack of sartorial elegance, spivs are usually the sharp dressers!

Mugginsthedog this is what you said earlier and I agree "The funding is expensive but the company probably had little choice."

You need capital to grow and given the current SP as was explained by GB, a fund raise not viable.

You are entitled to interperate the information as you wish as am I, but please refrain from name calling, it diminishes your arguments.

DVRG have not issued a statement saying the brokers 2022 revenues estimate needs to be revised.

My understanding of the RNS re directors getting paid in shares, is rather than take the shares, as they were entitled to in lieu of wages, they took wages instead. GB has then reinvested his wages in the company purchasing the £20k worth. It also avoided a dilution in shareholder value. The interims (H1 21)had a operational cash burn rate of of circa £400k per month and another £100k or so in investing activities. They also paid off a £1m loan. We do not know the cash burn rate for H2 but we do know revenues increased which should have reduced the operational cash burn rate. We aslo do not know the cash burn rate for investing activities but I would expect them to have increased as the company grows we will need to wait for finals to find out. Re the mezzanine loan facility, it is within norms for this type of finance, albeit more expensive than other forms of funding. The key for me is why take it, if it's to fund significant growth in revenues short term and these revenues generate profits to cover interest rates all good imv. If it is used to support day to day operational spend then it is not a good deal. We will find out soon enough with repayments due commence in September.

Whilst the UK only imports minimal gas and oil from Russia and the focus is likely to be on expanding renewables, european countries like Germany and Italy are not in the same position and in the medium term will require to secure gas and oil elsewhere and the north sea could be a viable option. Hope so, as PMG could be well placed to benefit. Need to wait and see!

From the RNS 27 CTM units have a capital value of £0.76m or £28,148 per unit. The lease value for the 27 units is £1.83m over five years or £13,555 per unit per year. The lease value over the 5 years of £67,775 includes consumables and maintenance. If 200 units a month sold then you are looking at annual revenues £32.5m in year 1. Year 2 £ 65m, year 5 £162.5m. What the actual number of units sold will be and the profit levels from these revenues are currently the unknown, but the potential could be significant.

MSYS are far from being out of the woods yet. It may have a market cap of £7m, it is still loss making currently, albeit improving. It did have cash in bank at the interim's, (supporting it's sp) but suspect less now. Whilst DVRG got a company today for £1.1m, with a EBTIDA of £200k. Mezzanine finance suitable for latter, as the funding costs can be met, not for the former (MSYS). In 6 months, or a year or so, MSYS maybe a viable target and if the price is right. In that case, a rights issue maybe more apt for a cash offer, imv, enabling all shareholders participation, should they wish.

Argylerich certainly agree slippage on projects is the norm, perhaps more so these days with so many supply chain issues around the world. Like any good management team these have been identified and action taken to minimise the impact. Securing manufacturing capacity, at what looks like a very attractive price given it's profitability, is a canny move imv.

GB was clear as to why this route of funding was taken in the proactive interview. He did say on track for scaling up production by end of Q2, it remains to be seen if they achieve 200 a month, we will see soon enough. What matters is we will have the production facilities and finance are in place to support the various business segments expansion. Now we need the revenues, so looking forward to positive news flow on this front in the coming months.

Argylerich perhaps if you look at page 15 of Trat's posting history you will see a post that answers your question. Apologies for intervening but I find Trat's posts informative and helpful.